A Randomized, Double Blind Phase II Trial of Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
Phase of Trial: Phase II
Latest Information Update: 02 Jan 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Temozolomide (Primary) ; Vitespen (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 23 Dec 2017 Planned End Date changed from 1 May 2019 to 1 May 2020.
- 22 Mar 2017 Status changed from not yet recruiting to recruiting.
- 20 Jan 2017 Planned initiation date changed from 1 Jan 2017 to 3 Jan 2017.